Secretary Wright visited PNNL's campus in Richland, Washington, late last year to meet with innovators in chemistry, biology, computing, and more.

The Genesis Mission will mobilize the Department of Energy’s 17 National Laboratories, industry, and academia to build an integrated discovery platform.

PNNL researchers are opening up a new front in the fight to stop viral pathogens, protecting people against multiple viruses.

Lauren Charles, a chief data scientist at PNNL, showcased the vital research coming out of her program at The National Academies Forum workshop in Washington, D.C., January 15–16, 2025.

Nine national laboratories, including PNNL, bring together over 1,000 scientists for a day to use AI to accelerate scientific discovery.

A cross-institutional team of scientists developed PeakQC, a new software tool for automated quality control of mass spectrometry data.

Neeraj Kumar discusses how AI can transform scientific research at the Platform for Advanced Scientific Computing Conference and Trillion Parameter Consortium European Workshop.

Ljiljana Paša-Tolić, a PNNL fellow, is the recipient of the 2024 International Mass Spectrometry Foundation’s Jochen Franzen Award. 

Researchers will explore climate, pathogens and energy-efficient microelectronics using 3 million node hours on the nation’s supercomputers.

Research at PNNL and the University of Texas at El Paso are addressing computational challenges of thinking beyond the list and developing bioagent-agnostic signatures to assess threats.

Vigorous exercise burns fat more in males than in females, but the benefits of exercise are broad for both sexes.

Scientists have learned more about how to protect the insulin-producing cells that die in patients with Type 1 diabetes.

Scientists have learned more about how drug resistance develops in patients with acute myeloid leukemia and how the process might be slowed.

The Rapid Assessment of Platform Technologies to Expedite Response project aims to prepare against future pandemics.

Data-driven autonomous technology to rapidly design and deliver antiviral interventions targeting SARS-CoV-2 to reduce drug discovery timeline and advance bio preparedness capabilities.

The virus that causes COVID-19 takes over the body’s fat-processing system and boosts cellular triglycerides as it causes disease.

Parallel graph neural networks identify protein-ligand 3-D structural interactions to aid in protein function prediction and drug discovery.

PNNL scientists publish paper and host workshops to share threat-agnostic vision for biodefense.